MBX Biosciences to Participate in Stifel 2023 Healthcare Conference

CARMEL, Ind., Oct. 31, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at the Stifel 2023 Healthcare Conference on Tuesday, November 14th, 2023, at 2:25 p.m. Eastern Time and will host 1-on-1 investor meetings.

About MBX Biosciences

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX’s pipeline includes its lead product candidate MBX 2109, which has completed Phase 1 development for the treatment of hypoparathyroidism, and MBX 1416, in Phase 1 development for the treatment of post-bariatric hypoglycemia. The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and X (formerly Twitter).

Media Contact:Ian StoneEvoke Canale[email protected]619-849-5388

Investor Contact:Irina KofflerLifeSci Advisors[email protected]917-734-7387

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• How Minecraft's Creator Economy Keeps Growing After 17 Years
• Bitcoin Targets $77K After a Short Squeeze as XRP Jumps 20% and Apeing Enters the Best Upcoming Crypto Presale Race